Corrigendum to: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (Clinical Pharmacology & Therapeutics, (2017), 101, 3, (341-358), 10.1002/cpt.602)

doi:10.1002/cpt.725

Corrigendum to: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (Clinical Pharmacology & Therapeutics, (2017), 101, 3, (341-358), 10.1002/cpt.602)

Clinical Pharmacy

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Citation (Scopus)

Abstract

Clin. Pharmacol. Ther. 101, 341–358 (2017); doi:10.1002/cpt.602. On page 344, under the heading “Cleveland Clinic's Personalized Medication Program”, the gene drug pair reported as “HLA-B*1502-abacavir” should be “HLA-B*5701-abacavir”. In the first row of Table 1 on page 347, under the column heading “Drug-gene pairs…”, the drug-gene pair “HLA-B*1501/abacavir” should be “HLA-B*5701/abacavir”. In Table 2 on page 353, in the “Antiepileptic” row, under the “Clinically relevant genetic interaction” column, “HLA-B*5701” should be “HLA-B*1502”. The authors regret these errors and thank Dr. Francesco Rucci for bringing them to their attention.

Original language	English
Number of pages	1
Journal	Clinical Pharmacology and Therapeutics
Volume	102
Issue number	1
DOIs	https://doi.org/10.1002/cpt.725
Publication status	Published - 1 Jul 2017

Access to Document

10.1002/cpt.725

Fingerprint

Dive into the research topics of 'Corrigendum to: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (Clinical Pharmacology & Therapeutics, (2017), 101, 3, (341-358), 10.1002/cpt.602)'. Together they form a unique fingerprint.

1 Citations
1 Article

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium
van der Wouden, C. H., Cambon-Thomsen, A., Cecchin, E., Cheung, K. C., Dávila-Fajardo, C. L., Deneer, V. H., Dolžan, V., Ingelman-Sundberg, M., Jönsson, S., Karlsson, M. O., Kriek, M., Mitropoulou, C., Patrinos, G. P., Pirmohamed, M., Samwald, M., Schaeffeler, E., Schwab, M., Steinberger, D., Stingl, J. & Sunder-Plassmann, G. & 6 others, Toffoli, G., Turner, R. M., van Rhenen, M. H., Swen, J. J., Guchelaar, H. J. & on behalf of the Ubiquitous Pharmacogenomics Consortium, 1 Mar 2017, In: Clinical Pharmacology and Therapeutics. 101, 3, p. 341-358 18 p.
Research output: Contribution to journal › Article › Academic › peer-review
78 Citations (Scopus)

Cite this

@article{6dffcbcb68ff49d391c3ccbbe428cca3,

title = "Corrigendum to: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (Clinical Pharmacology \& Therapeutics, (2017), 101, 3, (341-358), 10.1002/cpt.602)",

abstract = "Clin. Pharmacol. Ther. 101, 341–358 (2017); doi:10.1002/cpt.602. On page 344, under the heading “Cleveland Clinic's Personalized Medication Program”, the gene drug pair reported as “HLA-B*1502-abacavir” should be “HLA-B*5701-abacavir”. In the first row of Table 1 on page 347, under the column heading “Drug-gene pairs…”, the drug-gene pair “HLA-B*1501/abacavir” should be “HLA-B*5701/abacavir”. In Table 2 on page 353, in the “Antiepileptic” row, under the “Clinically relevant genetic interaction” column, “HLA-B*5701” should be “HLA-B*1502”. The authors regret these errors and thank Dr. Francesco Rucci for bringing them to their attention.",

author = "\{van der Wouden\}, \{C. H.\} and A. Cambon-Thomsen and E. Cecchin and Cheung, \{K. C.\} and D{\'a}vila-Fajardo, \{C. L.\} and Deneer, \{V. H.\} and V. Dol{\v z}an and M. Ingelman-Sundberg and S. J{\"o}nsson and Karlsson, \{M. O.\} and M. Kriek and C. Mitropoulou and Patrinos, \{G. P.\} and M. Pirmohamed and M. Samwald and E. Schaeffeler and M. Schwab and D. Steinberger and J. Stingl and G. Sunder-Plassmann and G. Toffoli and Turner, \{R. M.\} and \{van Rhenen\}, \{M. H.\} and Swen, \{J. J.\} and Guchelaar, \{H. J.\}",

year = "2017",

month = jul,

day = "1",

doi = "10.1002/cpt.725",

language = "English",

volume = "102",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "1",

}

Corrigendum to: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (Clinical Pharmacology & Therapeutics, (2017), 101, 3, (341-358), 10.1002/cpt.602). /.
In: Clinical Pharmacology and Therapeutics, Vol. 102, No. 1, 01.07.2017.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Corrigendum to

T2 - Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (Clinical Pharmacology & Therapeutics, (2017), 101, 3, (341-358), 10.1002/cpt.602)

AU - van der Wouden, C. H.

AU - Cambon-Thomsen, A.

AU - Cecchin, E.

AU - Cheung, K. C.

AU - Dávila-Fajardo, C. L.

AU - Deneer, V. H.

AU - Dolžan, V.

AU - Ingelman-Sundberg, M.

AU - Jönsson, S.

AU - Karlsson, M. O.

AU - Kriek, M.

AU - Mitropoulou, C.

AU - Patrinos, G. P.

AU - Pirmohamed, M.

AU - Samwald, M.

AU - Schaeffeler, E.

AU - Schwab, M.

AU - Steinberger, D.

AU - Stingl, J.

AU - Sunder-Plassmann, G.

AU - Toffoli, G.

AU - Turner, R. M.

AU - van Rhenen, M. H.

AU - Swen, J. J.

AU - Guchelaar, H. J.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Clin. Pharmacol. Ther. 101, 341–358 (2017); doi:10.1002/cpt.602. On page 344, under the heading “Cleveland Clinic's Personalized Medication Program”, the gene drug pair reported as “HLA-B*1502-abacavir” should be “HLA-B*5701-abacavir”. In the first row of Table 1 on page 347, under the column heading “Drug-gene pairs…”, the drug-gene pair “HLA-B*1501/abacavir” should be “HLA-B*5701/abacavir”. In Table 2 on page 353, in the “Antiepileptic” row, under the “Clinically relevant genetic interaction” column, “HLA-B*5701” should be “HLA-B*1502”. The authors regret these errors and thank Dr. Francesco Rucci for bringing them to their attention.

AB - Clin. Pharmacol. Ther. 101, 341–358 (2017); doi:10.1002/cpt.602. On page 344, under the heading “Cleveland Clinic's Personalized Medication Program”, the gene drug pair reported as “HLA-B*1502-abacavir” should be “HLA-B*5701-abacavir”. In the first row of Table 1 on page 347, under the column heading “Drug-gene pairs…”, the drug-gene pair “HLA-B*1501/abacavir” should be “HLA-B*5701/abacavir”. In Table 2 on page 353, in the “Antiepileptic” row, under the “Clinically relevant genetic interaction” column, “HLA-B*5701” should be “HLA-B*1502”. The authors regret these errors and thank Dr. Francesco Rucci for bringing them to their attention.

UR - https://www.scopus.com/pages/publications/85020806319

U2 - 10.1002/cpt.725

DO - 10.1002/cpt.725

M3 - Comment/Letter to the editor

C2 - 30239993

AN - SCOPUS:85020806319

SN - 0009-9236

VL - 102

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 1

ER -

Corrigendum to: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium (Clinical Pharmacology & Therapeutics, (2017), 101, 3, (341-358), 10.1002/cpt.602)

Abstract

Access to Document

Other files and links

Fingerprint

Research output

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Cite this